TriSalus Life Sciences Inc. (NASDAQ:TLSI) is gearing up for its quarterly earnings release, with a focus on its innovative approach to oncology treatment.

Here are three key insights from the upcoming financial announcement and recent company activities:

- Wall Street anticipates an earnings per share (EPS) of -$0.17 and projected revenue of approximately $11.76 million.

- Despite a negative price-to-earnings (P/E) ratio of -4.67, TLSI is actively engaging in investor relations events, including the Canaccord Genuity MedTech, Diagnostics, and Digital Health conference.

- The company is hosting a virtual event to discuss the TriNav Infusion System, highlighting its commitment to improving solid tumor treatment outcomes.

TriSalus Life Sciences Inc. (NASDAQ:TLSI) specializes in oncology, particularly in integrating novel delivery technology with standard care therapies for solid tumor treatment. The company is set to release its quarterly earnings on November 13, 2025. Wall Street's expectations are set at an earnings per share (EPS) of -$0.17, with projected revenue of approximately $11.76 million.

Despite a negative price-to-earnings (P/E) ratio of -4.67, TLSI continues to engage with investors and stakeholders. The company's participation in the Canaccord Genuity MedTech, Diagnostics, and Digital Health conference in November, as reported by BusinessWire, underscores their commitment to maintaining strong investor relations. TLSI is also hosting a virtual key opinion leader (KOL) event on November 12, 2025, to discuss the TriNav Infusion System, used for treating uterine fibroids. This event, featuring insights from Dr. Nicole Lamparello and Dr. Francis Kang, emphasizes the company's dedication to improving treatment outcomes for patients with solid tumors.

Financially, TLSI's price-to-sales ratio stands at about 4.66, indicating that investors are willing to pay $4.66 for every dollar of sales. The enterprise value to sales ratio is around 4.86, reflecting the company's valuation relative to its sales. However, the enterprise value to operating cash flow ratio is approximately -6.17, highlighting negative operating cash flow.

TLSI's earnings yield is about -21.44%, indicative of negative earnings relative to its share price. The debt-to-equity ratio is approximately -1.73, suggesting more liabilities than equity. However, the current ratio of around 4.08 indicates a strong ability to cover short-term liabilities with short-term assets.